Please ensure Javascript is enabled for purposes of website accessibility
Taylor Carmichael

Taylor Carmichael


Taylor Carmichael is a former attorney and filmmaker. He's the author of a line of murder mysteries, including Whodidit in the Supreme Court? and Whodidit With a Senator? The majority of what he knows about stocks he learned right here at the Motley Fool.

Recent articles


Can Novavax's Coronavirus Vaccine Be Valued?

The race for a COVID-19 vaccine is wildly unpredictable and full of variables.


The Top 2 Contrarian Stocks to Buy Right Now

The COVID-19 lockdown has hammered the stocks of Park Hotels & Resorts and Royal Caribbean, creating a strong buying opportunity for 2021.


Accelerate Diagnostics Announces Emergency Use Authorization for Covid-19 Antibody Test

This new testing platform will speed up health checks by determining whether asymptomatic people have COVID-19 antibodies in 30 minutes.


Forget Livongo: This Might Be a Stronger Telehealth Stock

Ontrak's stock price has already tripled in 2020, and there are reasons to think it might have an edge over its larger peer.


Buy Alert: Ubisoft Stock Is Heading Higher

The French video game company has promising releases coming up to boost revenue through Christmas and into 2021.


Novavax Stock Is Up on Deal With SK Bioscience

The company is adding to the already-massive production capacity it has lined up for its COVID-19 vaccine candidate.


Why in the World Is Novavax Stock Up 4,000%?

The small-cap biotech has emerged as one of the favorites in the race for a COVID-19 vaccine.


These Stocks Would Have Doubled Your Money Last Year

Axsome Therapeutics and EverQuote had two of the biggest stock gains in 2019. Are they still buys today?


Tiny Arbutus Biopharma Wins Patent Litigation Fight with COVID-19 Vaccine Implications

The ruling means Moderna may have to pay royalties on its mRNA-based vaccines -- including its coronavirus candidate.


Why Was Novavax Awarded Almost $2 Billion in Free Money?

Operation Warp Speed (OWS) and the Coalition for Epidemic Preparedness Innovations (CEPI) both selected Novavax for their highest grant awards.


Beware! Your Coronavirus Stock Might Be Crushed by the FDA

Some of the companies pursuing a coronavirus vaccine will end up far more valuable than they are today -- while others might be a disaster waiting to happen.


These 2 Coronavirus Stocks Could Soar in the Second Half of 2020

Both Moderna and Vaxart are expecting data readouts that will send the stocks skyrocketing -- if the news is positive.


3 Green Flags for Novavax's Future

There are good reasons to consider this small biotech an emerging favorite in the COVID-19 vaccine race.


Better Coronavirus Stock: Altimmune vs. Vaxart

Both of these small-cap vaccine stocks are up big in 2020.


Here's the Surprising Coronavirus Stock You'll Really Want to Own

It's a small-cap biotech that specializes in vaccines.


Wall Street Has Given Up on These 2 Stocks, and That's a Huge Mistake

Why StoneCo and bluebird bio are wonderful buys right now.


If You Invested $1,000 in Dexcom's IPO, This Is How Much Money You'd Have Now

Even small investments can have a big payoff down the road.


Should I Sell Novavax Shares?

I'm up 1,340% in nine months on this investment. Is it time to take some profits?


2 Stocks That Could Make You Rich

Why Adaptive Biotechnologies and Smartsheet will be mega-cap stocks in the future.


2 Top Stocks Under $5

Here's why you might want to invest in Planet 13 and W&T Offshore.